Posts by Jim Miller

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

CDMO Acquisitions Build Strategic Supplier Base

By Jim Miller, President, PharmSource Reprinted with permission from Pharmaceutical Technology CDMO Acquisitions Build Strategic Supplier Base Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma. November 2017 This has been another big year for acquisitions in the contract development and manufacturing organization (CDMO) industry. In the first three quarters of 2017, there […]

Learn more

Up and Away, M&A

Mergers and acquisitions are positive for the CDMO industry, but there is a downside. Mergers and acquisitions (M&A) are a central feature of the contract development and manufacturing (CDMO) industry today. Several new deals are being announced every month, some of them quite substantial, and these deals are reshaping the industry. CDMOs are in great […]

Learn more

CMOs Must Embrace Flexible Manufacturing

The need for flexibility in manufacturing arrangements and technologies has never been greater. New products are more technically challenging, produced in smaller volumes, and subject to great market uncertainty stemming from competing therapies and reimbursement risk. Contract development and manufacturing organizations (CDMOs) need to respond in both technical capabilities and business model flexibility to address […]

Learn more

Contract Manufacturing Through the Years

How has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hold? The 40 years during which Pharmaceutical Technology has served the bio/pharmaceutical industry have been years of momentous growth and change in the way drugs are discovered, developed, manufactured, and sold. Contract development and manufacturing organizations (CDMOs) have long […]

Learn more

AMRI Sold to PE Firms

Albany Molecular Research Inc. (AMRI) is being taken private in a deal that values the company at $922 million. The buyers, private equity firms The Carlyle Group and GTCR, are newcomers to the contract development and manufacturing organization (CDMO) space, although Carlyle also owns clinical contract research organization (CRO) PPD Inc. The investors are paying […]

Learn more

CMOs and CROs Have Different Trajectories

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate. A growing number of observers, including the Wall Street analysts that follow the publicly-traded contract research organizations (CROs) and contract manufacturing organizations (CMOs), have made statements recently suggesting that the CMO industry is following the […]

Learn more

Strong Economic Growth Draws Pharma Companies to Malaysia

A rapidly growing pharma market and environment friendly to clinical trials are among the features that are attracting a growing number of multinational pharmaceutical companies to Malaysia. However, those pluses are balanced by decided favoritism toward domestic production, seen in government supply contracts and tax codes. According to a September 2016 report by PharmSource’s colleagues […]

Learn more

NDA Outsourcing Up, Despite NME Decline

In 2016, outsourced dose form manufacturing of NDA approvals reached 60%, some 10% higher than the five-year average. This and other insights into CMO performance were revealed in PharmSource’s recently published CMO Scorecard. In what proved to be a mediocre year for drug approvals, the increase in outsourcing levels was restricted to the manufacture of […]

Learn more

Will Pharma Manufacturing Move Back to the US?

Moving global manufacturing operations may be more complicated than it appears. The bio/pharmaceutical industry is still buzzing about President Trump’s meeting with pharmaceutical executives on Jan. 31, 20171. While promising the industry lower taxes and less regulation, the President emphasized that those benefits will come only if the industry lowers drug prices and moves more […]

Learn more

AGC Acquires CMC Biologics

AGC Asahi Glass has agreed to acquire biomanufacturer CMC Biologics in a deal valued at ¥60 billion ($500 million). PharmSource estimates that the price represents a multiple of about 3.3x revenues and more than 10x EBITDA. The selling shareholders are three private equity firms: Monitor Clipper Partners; European Equity Partners; and Innoven Partenaires. Closing is […]

Learn more